Detection rate, pattern of relapse and influence on therapeutic decision of PSMA PET/CT in patients affected by biochemical recurrence after radical prostatectomy, a retrospective case series
Aims 68 Ga-Prostate-specific membrane antigen (PSMA) PET/CT is widely used in patients with biochemical recurrence (BCR) after radical prostatectomy. We collected data about patients staged with PSMA PET/CT after BCR (PSA 7 ( p = 0.004) and TTR
Gespeichert in:
| Veröffentlicht in: | Clinical & translational oncology 2021-02, Vol.23 (2), p.364-371 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 371 |
|---|---|
| container_issue | 2 |
| container_start_page | 364 |
| container_title | Clinical & translational oncology |
| container_volume | 23 |
| creator | Francolini, G. Detti, B. Bottero, M. Zilli, T. Lancia, A. Bruni, A. Borghesi, S. Mariotti, M. Castellucci, P. Fanti, S. Filippi, A. R. Teriaca, M. A. Maragna, V. Aristei, C. Mazzeo, E. Livi, L. Ingrosso, G. |
| description | Aims
68
Ga-Prostate-specific membrane antigen (PSMA) PET/CT is widely used in patients with biochemical recurrence (BCR) after radical prostatectomy. We collected data about patients staged with PSMA PET/CT after BCR (PSA 7 (
p
= 0.004) and TTR |
| doi_str_mv | 10.1007/s12094-020-02427-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2419098912</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2419098912</sourcerecordid><originalsourceid>FETCH-LOGICAL-c347t-b4588144faebc81ac463517ce4b16078eb78d9a74f5c27c746e462cd63a82df83</originalsourceid><addsrcrecordid>eNp9Uctu1DAUtRCIlpYfYIG8ZNFQ23FiZ1lNy0NqRaUOEjvLca6pq7ywHaT5On6Nm5mBZReWrXvPyzqEvOPsI2dMXSYuWCMLJhgeKVQhXpBTXjdNUbKqenl8M6l_nJA3KT0xnNacvyYnpaiRpepT8ucaMrgcppFGm-GCzjZniCOdPI3Q2zkBtWNHw-j7BUYHFJH5EaKdYcnB0Q5cSCsdCfcPd1f0_mZ7udkiYZUKMOZErffoAR1td7QNk3uEITjbo4FbYtyrWo-uGKHbL-Y4pWzXYNOwu6AWkRlH85r0N1BnMVWCGCCdk1fe9gneHu8z8v3TzXbzpbj99vnr5uq2cKVUuWhlpTWX0ltonebWybqsuHIgW14zpaFVumuskr5yQjkla5C1cF1dWi06r8sz8uGgi9F-LZCyGUJy0Pd2hGlJRkjesEY3XCBUHKAOI6cI3swxDDbuDGdmLc4cijNYgdkXZ1bS-6P-0g7Q_af8awoB5QGQcDX-hGiepiWO-OfnZP8C74undw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2419098912</pqid></control><display><type>article</type><title>Detection rate, pattern of relapse and influence on therapeutic decision of PSMA PET/CT in patients affected by biochemical recurrence after radical prostatectomy, a retrospective case series</title><source>SpringerLink Journals - AutoHoldings</source><creator>Francolini, G. ; Detti, B. ; Bottero, M. ; Zilli, T. ; Lancia, A. ; Bruni, A. ; Borghesi, S. ; Mariotti, M. ; Castellucci, P. ; Fanti, S. ; Filippi, A. R. ; Teriaca, M. A. ; Maragna, V. ; Aristei, C. ; Mazzeo, E. ; Livi, L. ; Ingrosso, G.</creator><creatorcontrib>Francolini, G. ; Detti, B. ; Bottero, M. ; Zilli, T. ; Lancia, A. ; Bruni, A. ; Borghesi, S. ; Mariotti, M. ; Castellucci, P. ; Fanti, S. ; Filippi, A. R. ; Teriaca, M. A. ; Maragna, V. ; Aristei, C. ; Mazzeo, E. ; Livi, L. ; Ingrosso, G.</creatorcontrib><description>Aims
68
Ga-Prostate-specific membrane antigen (PSMA) PET/CT is widely used in patients with biochemical recurrence (BCR) after radical prostatectomy. We collected data about patients staged with PSMA PET/CT after BCR (PSA < 1 ng/ml) in four different institutes. Impact of baseline features (Gleason score, risk classification, PSA at recurrence, PSA doubling time and time to recurrence) was explored to understand predictive factors of (PSMA) PET/CT positivity. Impact of restaging on following treatment approaches was reported.
Results
92 patients were included. PSMA PET/CT detection rate was 56.5% and low-volume disease (≤ 3 non-visceral lesions) was detected in 52.2% of patients. After positive scan, 13.5% of patients still lies on observation, ADT alone was administered in 30.8% of cases, Stereotactic body RT (SBRT) alone was delivered to 44.2% of patients and 11.5% of patients underwent concomitant SBRT and ADT. Seven patients underwent conventional salvage prostate bed RT. Chi-squared test showed a higher rate of positive PSMA PET/CT for patients with Gleason score > 7 (
p
= 0.004) and TTR < 29.5 months (
p
= 0.003).
Conclusions
PSMA PET/CT showed a high detection rate. This influenced clinical management in a significant percentage of patients, allowing treatment tailoring on the basis of imaging.</description><identifier>ISSN: 1699-048X</identifier><identifier>EISSN: 1699-3055</identifier><identifier>DOI: 10.1007/s12094-020-02427-2</identifier><identifier>PMID: 32602076</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Medicine ; Medicine & Public Health ; Oncology ; Research Article</subject><ispartof>Clinical & translational oncology, 2021-02, Vol.23 (2), p.364-371</ispartof><rights>Federación de Sociedades Españolas de Oncología (FESEO) 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c347t-b4588144faebc81ac463517ce4b16078eb78d9a74f5c27c746e462cd63a82df83</citedby><cites>FETCH-LOGICAL-c347t-b4588144faebc81ac463517ce4b16078eb78d9a74f5c27c746e462cd63a82df83</cites><orcidid>0000-0002-1784-7203</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12094-020-02427-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12094-020-02427-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,778,782,27907,27908,41471,42540,51302</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32602076$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Francolini, G.</creatorcontrib><creatorcontrib>Detti, B.</creatorcontrib><creatorcontrib>Bottero, M.</creatorcontrib><creatorcontrib>Zilli, T.</creatorcontrib><creatorcontrib>Lancia, A.</creatorcontrib><creatorcontrib>Bruni, A.</creatorcontrib><creatorcontrib>Borghesi, S.</creatorcontrib><creatorcontrib>Mariotti, M.</creatorcontrib><creatorcontrib>Castellucci, P.</creatorcontrib><creatorcontrib>Fanti, S.</creatorcontrib><creatorcontrib>Filippi, A. R.</creatorcontrib><creatorcontrib>Teriaca, M. A.</creatorcontrib><creatorcontrib>Maragna, V.</creatorcontrib><creatorcontrib>Aristei, C.</creatorcontrib><creatorcontrib>Mazzeo, E.</creatorcontrib><creatorcontrib>Livi, L.</creatorcontrib><creatorcontrib>Ingrosso, G.</creatorcontrib><title>Detection rate, pattern of relapse and influence on therapeutic decision of PSMA PET/CT in patients affected by biochemical recurrence after radical prostatectomy, a retrospective case series</title><title>Clinical & translational oncology</title><addtitle>Clin Transl Oncol</addtitle><addtitle>Clin Transl Oncol</addtitle><description>Aims
68
Ga-Prostate-specific membrane antigen (PSMA) PET/CT is widely used in patients with biochemical recurrence (BCR) after radical prostatectomy. We collected data about patients staged with PSMA PET/CT after BCR (PSA < 1 ng/ml) in four different institutes. Impact of baseline features (Gleason score, risk classification, PSA at recurrence, PSA doubling time and time to recurrence) was explored to understand predictive factors of (PSMA) PET/CT positivity. Impact of restaging on following treatment approaches was reported.
Results
92 patients were included. PSMA PET/CT detection rate was 56.5% and low-volume disease (≤ 3 non-visceral lesions) was detected in 52.2% of patients. After positive scan, 13.5% of patients still lies on observation, ADT alone was administered in 30.8% of cases, Stereotactic body RT (SBRT) alone was delivered to 44.2% of patients and 11.5% of patients underwent concomitant SBRT and ADT. Seven patients underwent conventional salvage prostate bed RT. Chi-squared test showed a higher rate of positive PSMA PET/CT for patients with Gleason score > 7 (
p
= 0.004) and TTR < 29.5 months (
p
= 0.003).
Conclusions
PSMA PET/CT showed a high detection rate. This influenced clinical management in a significant percentage of patients, allowing treatment tailoring on the basis of imaging.</description><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Research Article</subject><issn>1699-048X</issn><issn>1699-3055</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9Uctu1DAUtRCIlpYfYIG8ZNFQ23FiZ1lNy0NqRaUOEjvLca6pq7ywHaT5On6Nm5mBZReWrXvPyzqEvOPsI2dMXSYuWCMLJhgeKVQhXpBTXjdNUbKqenl8M6l_nJA3KT0xnNacvyYnpaiRpepT8ucaMrgcppFGm-GCzjZniCOdPI3Q2zkBtWNHw-j7BUYHFJH5EaKdYcnB0Q5cSCsdCfcPd1f0_mZ7udkiYZUKMOZErffoAR1td7QNk3uEITjbo4FbYtyrWo-uGKHbL-Y4pWzXYNOwu6AWkRlH85r0N1BnMVWCGCCdk1fe9gneHu8z8v3TzXbzpbj99vnr5uq2cKVUuWhlpTWX0ltonebWybqsuHIgW14zpaFVumuskr5yQjkla5C1cF1dWi06r8sz8uGgi9F-LZCyGUJy0Pd2hGlJRkjesEY3XCBUHKAOI6cI3swxDDbuDGdmLc4cijNYgdkXZ1bS-6P-0g7Q_af8awoB5QGQcDX-hGiepiWO-OfnZP8C74undw</recordid><startdate>20210201</startdate><enddate>20210201</enddate><creator>Francolini, G.</creator><creator>Detti, B.</creator><creator>Bottero, M.</creator><creator>Zilli, T.</creator><creator>Lancia, A.</creator><creator>Bruni, A.</creator><creator>Borghesi, S.</creator><creator>Mariotti, M.</creator><creator>Castellucci, P.</creator><creator>Fanti, S.</creator><creator>Filippi, A. R.</creator><creator>Teriaca, M. A.</creator><creator>Maragna, V.</creator><creator>Aristei, C.</creator><creator>Mazzeo, E.</creator><creator>Livi, L.</creator><creator>Ingrosso, G.</creator><general>Springer International Publishing</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1784-7203</orcidid></search><sort><creationdate>20210201</creationdate><title>Detection rate, pattern of relapse and influence on therapeutic decision of PSMA PET/CT in patients affected by biochemical recurrence after radical prostatectomy, a retrospective case series</title><author>Francolini, G. ; Detti, B. ; Bottero, M. ; Zilli, T. ; Lancia, A. ; Bruni, A. ; Borghesi, S. ; Mariotti, M. ; Castellucci, P. ; Fanti, S. ; Filippi, A. R. ; Teriaca, M. A. ; Maragna, V. ; Aristei, C. ; Mazzeo, E. ; Livi, L. ; Ingrosso, G.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c347t-b4588144faebc81ac463517ce4b16078eb78d9a74f5c27c746e462cd63a82df83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Research Article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Francolini, G.</creatorcontrib><creatorcontrib>Detti, B.</creatorcontrib><creatorcontrib>Bottero, M.</creatorcontrib><creatorcontrib>Zilli, T.</creatorcontrib><creatorcontrib>Lancia, A.</creatorcontrib><creatorcontrib>Bruni, A.</creatorcontrib><creatorcontrib>Borghesi, S.</creatorcontrib><creatorcontrib>Mariotti, M.</creatorcontrib><creatorcontrib>Castellucci, P.</creatorcontrib><creatorcontrib>Fanti, S.</creatorcontrib><creatorcontrib>Filippi, A. R.</creatorcontrib><creatorcontrib>Teriaca, M. A.</creatorcontrib><creatorcontrib>Maragna, V.</creatorcontrib><creatorcontrib>Aristei, C.</creatorcontrib><creatorcontrib>Mazzeo, E.</creatorcontrib><creatorcontrib>Livi, L.</creatorcontrib><creatorcontrib>Ingrosso, G.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical & translational oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Francolini, G.</au><au>Detti, B.</au><au>Bottero, M.</au><au>Zilli, T.</au><au>Lancia, A.</au><au>Bruni, A.</au><au>Borghesi, S.</au><au>Mariotti, M.</au><au>Castellucci, P.</au><au>Fanti, S.</au><au>Filippi, A. R.</au><au>Teriaca, M. A.</au><au>Maragna, V.</au><au>Aristei, C.</au><au>Mazzeo, E.</au><au>Livi, L.</au><au>Ingrosso, G.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Detection rate, pattern of relapse and influence on therapeutic decision of PSMA PET/CT in patients affected by biochemical recurrence after radical prostatectomy, a retrospective case series</atitle><jtitle>Clinical & translational oncology</jtitle><stitle>Clin Transl Oncol</stitle><addtitle>Clin Transl Oncol</addtitle><date>2021-02-01</date><risdate>2021</risdate><volume>23</volume><issue>2</issue><spage>364</spage><epage>371</epage><pages>364-371</pages><issn>1699-048X</issn><eissn>1699-3055</eissn><abstract>Aims
68
Ga-Prostate-specific membrane antigen (PSMA) PET/CT is widely used in patients with biochemical recurrence (BCR) after radical prostatectomy. We collected data about patients staged with PSMA PET/CT after BCR (PSA < 1 ng/ml) in four different institutes. Impact of baseline features (Gleason score, risk classification, PSA at recurrence, PSA doubling time and time to recurrence) was explored to understand predictive factors of (PSMA) PET/CT positivity. Impact of restaging on following treatment approaches was reported.
Results
92 patients were included. PSMA PET/CT detection rate was 56.5% and low-volume disease (≤ 3 non-visceral lesions) was detected in 52.2% of patients. After positive scan, 13.5% of patients still lies on observation, ADT alone was administered in 30.8% of cases, Stereotactic body RT (SBRT) alone was delivered to 44.2% of patients and 11.5% of patients underwent concomitant SBRT and ADT. Seven patients underwent conventional salvage prostate bed RT. Chi-squared test showed a higher rate of positive PSMA PET/CT for patients with Gleason score > 7 (
p
= 0.004) and TTR < 29.5 months (
p
= 0.003).
Conclusions
PSMA PET/CT showed a high detection rate. This influenced clinical management in a significant percentage of patients, allowing treatment tailoring on the basis of imaging.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>32602076</pmid><doi>10.1007/s12094-020-02427-2</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-1784-7203</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1699-048X |
| ispartof | Clinical & translational oncology, 2021-02, Vol.23 (2), p.364-371 |
| issn | 1699-048X 1699-3055 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2419098912 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Medicine Medicine & Public Health Oncology Research Article |
| title | Detection rate, pattern of relapse and influence on therapeutic decision of PSMA PET/CT in patients affected by biochemical recurrence after radical prostatectomy, a retrospective case series |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T23%3A55%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Detection%20rate,%20pattern%20of%20relapse%20and%20influence%20on%20therapeutic%20decision%20of%20PSMA%20PET/CT%20in%20patients%20affected%20by%20biochemical%20recurrence%20after%20radical%20prostatectomy,%20a%20retrospective%20case%20series&rft.jtitle=Clinical%20&%20translational%20oncology&rft.au=Francolini,%20G.&rft.date=2021-02-01&rft.volume=23&rft.issue=2&rft.spage=364&rft.epage=371&rft.pages=364-371&rft.issn=1699-048X&rft.eissn=1699-3055&rft_id=info:doi/10.1007/s12094-020-02427-2&rft_dat=%3Cproquest_cross%3E2419098912%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2419098912&rft_id=info:pmid/32602076&rfr_iscdi=true |